Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
NCT00645918 · View on ClinicalTrials.gov ↗
Study Summary
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
Conditions Studied
Interventions
- DRUG placebo
- DRUG clopidogrel
Study Locations (20)
California
- Scripps Green Hospital — La Jolla
- El Camino Hospital — Mountain View
- UC Davis Medical Center — Sacramento
- Sacramento Heart and Vascular Research Center — Sacramento
- UCSD Medical Center — San Diego
- Alvarado Hospital — San Diego
- San Francisco General Hospital — San Francisco
- UCSF Moffitt-Long Hospital — San Francisco
- Santa Barbara Cottage Hospital — Santa Barbara
- Torrance Memorial Medical Center — Torrance
Florida
- Clearwater Cardiovascular and Interventional Consultants — Clearwater
- University of Florida Health Science Center — Jacksonville
- Cardiology Research Associates — Ormond Beach
Arizona
- Scottsdale Health Care - Osborn Campus — Scottsdale
- Scottsdale Health Care - Shea Campus — Scottsdale
Connecticut
- Bridgeport Hospital — Bridgeport
- Danbury Hospital — Danbury
Alabama
- University of Alabama at Birmingham — Birmingham
Delaware
- Christiana Care Hospital — Newark
District of Columbia
- Washington Hospital Center — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-10 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645918
The ClinicalTrials.gov registry entry for NCT00645918 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accumetrics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00645918 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00645918 about?
NCT00645918 is a clinical study titled "GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety". The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
What is the current status of trial NCT00645918?
This trial is currently completed. It is a NA study. The enrollment target is 2,800 participants. The study started on 2008-06. Estimated completion is 2010-10.
What conditions does trial NCT00645918 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome, Coronary Arteriosclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00645918?
The interventions under investigation include: placebo (DRUG), clopidogrel (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00645918?
This trial is sponsored by Accumetrics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00645918 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.